Clinical trial
Hepatic Artery Infusion Gemcitabine and Floxuridine in Patients With Nasopharyngeal Carcinoma Liver Metastases
NCT03876574 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Hepatic Artery Infusion Gemcitabine and Floxuridine in Patients With Nasopharyngeal Carcinoma Liver Metastases
- Lead sponsor
- Xiangya Hospital of Central South University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 1, 2011
- Completion date
- December 31, 2017
- Enrollment
- 16 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.